News
XBIO
3.776
-1.92%
-0.074
Weekly Report: what happened at XBIO last week (0415-0419)?
Weekly Report · 4d ago
Weekly Report: what happened at XBIO last week (0408-0412)?
Weekly Report · 04/15 12:01
Weekly Report: what happened at XBIO last week (0401-0405)?
Weekly Report · 04/08 12:08
Weekly Report: what happened at XBIO last week (0325-0329)?
Weekly Report · 04/01 12:04
Weekly Report: what happened at XBIO last week (0318-0322)?
Weekly Report · 03/25 12:08
CORRECTION: On Friday, Xenetic Biosciences Q4 GAAP EPS $(0.77) Beats $(0.87) Estimate, Sales $671.96K Miss $680.00K Estimate
Xenetic Biosciences (NASDAQ:XBIO) reported quarterly losses of $0.77 per share. The company reported quarterly sales of $671.96 thousand. Xenetic beat the analyst consensus estimate of $680.00 thousand by 11.49 percent.
Benzinga · 03/25 10:59
Xenetic Biosciences, Inc. Under Pressure: Shareholder Activism Threatens Stability and Financial Future
TipRanks · 03/23 06:00
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Xenetic Biosciences (XBIO) and Dianthus Therapeutics (DNTH)
TipRanks · 03/22 12:31
Xenetic Biosciences reports FY results
Seeking Alpha · 03/22 12:14
Xenetic Biosciences Q4 EPS $0.77 Beats $(0.87) Estimate, Sales $671.96K Miss $680.00K Estimate
Xenetic Biosciences (NASDAQ:XBIO) reported quarterly earnings of $0.77 per share. The company reported quarterly sales of $671.96 thousand. Xenetic beat the analyst consensus estimate of $680.00 thousand by 1.18 percent.
Benzinga · 03/22 12:03
XBIO Stock Earnings: Xenetic Biosciences Beats EPS, Misses Revenue for Q4 2023
Xenetic Biosciences reported earnings per share of 77 cents for the fourth quarter of 2023. The company reported revenue of $671,963. This was 1.18% worse than the analyst estimate for revenue. Xenetic B biosciences also reported results for the third quarter of 2018.
Investorplace · 03/22 11:53
Xenetic Dips on Full-Year Results
Xenetic Biosciences, Inc. Shares fell 30 cents, or 7.6%, to $3.65 on Friday. The company reported its financial results for the year ended December 31, 2023. XBIO is focused on advancing innovative immune-oncology technologies.
Barchart · 03/22 08:56
Xenetic Biosciences Inc reports results for the quarter ended in December - Earnings Summary
Xenetic Biosciences Inc reports results for the quarter ended in December. Revenue rose 38.3% to $672.00 thousand from a year ago. The company reported a quarterly loss of $1.17 million. Xenetic B biosciences shares had risen by 21.7% this quarter.
Reuters · 03/21 21:51
Weekly Report: what happened at XBIO last week (0311-0315)?
Weekly Report · 03/18 12:06
Weekly Report: what happened at XBIO last week (0304-0308)?
Weekly Report · 03/11 12:01
Weekly Report: what happened at XBIO last week (0226-0301)?
Weekly Report · 03/04 12:05
Weekly Report: what happened at XBIO last week (0219-0223)?
Weekly Report · 02/26 12:23
Weekly Report: what happened at XBIO last week (0212-0216)?
Weekly Report · 02/19 12:26
Xenetic Biosciences Shares Insights on Oncology Platform
TipRanks · 02/12 14:35
Weekly Report: what happened at XBIO last week (0205-0209)?
Weekly Report · 02/12 12:11
More
Webull provides a variety of real-time XBIO stock news. You can receive the latest news about Xenetic Biosciences Inc through multiple platforms. This information may help you make smarter investment decisions.
About XBIO
Xenetic Biosciences, Inc. is a biopharmaceutical company. The Company is focused on advancing immune-oncology technologies addressing hard to treat cancers. The Company's DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression. It is focused on advancing the development of its DNase platform toward a first-in-human, multicenter, dose escalation and dose-expansion study of IV rhDNase I in subjects with locally advanced or metastatic solid tumors. Its systemic DNase program is initially targeting multi-billion-dollar indications including pancreatic cancer, which includes pancreatic ductal adenocarcinoma (PDAC), colorectal carcinoma (CRC) and other gastrointestinal cancers. These are all cancer indications with significant unmet need, and with opportunities for substantial improvement of the available therapeutic options.